Investigating how glioma tumors respond to immunotherapy
MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy
This study is looking at why some people with glioblastoma, a type of brain cancer, benefit from immunotherapy while others don’t, by examining tumor samples and patient information to find clues that could help improve treatment for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10757385 on NIH RePORTER |
What this research studies
This research focuses on understanding why some patients with glioblastoma, a type of brain cancer, respond to immunotherapy while others do not. By analyzing tumor samples and patient data, the researchers aim to identify specific molecular markers that predict a positive response to treatment. They will also explore the role of CD8 T-cells in tumor progression and how their depletion affects tumor behavior. This approach combines laboratory analysis with patient outcomes to improve treatment strategies for glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who are considering or have undergone PD1 blockade immunotherapy.
Not a fit: Patients with glioblastoma who are not eligible for immunotherapy or have not received a diagnosis of recurrent glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for glioblastoma patients, improving survival rates.
How similar studies have performed: Previous studies have shown that certain patients with glioblastoma can respond positively to immunotherapy, indicating potential for success in this research approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Sonabend, Adam M — Northwestern University at Chicago
- Study coordinator: Sonabend, Adam M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.